Skip to main content
. 2005 Jul;49(7):2598–2605. doi: 10.1128/AAC.49.7.2598-2605.2005

TABLE 1.

MICs and molecular results for all P. mirabilis isolates causing BSI during the study period (January 1997 to June 2004)

Isolate MIC of antimicrobial agent (μg/ml)a
Type of enzymes produced
AMP SAM AMC FOX PIP TZP CRO CTX CTL CAZ TZL FEP IPM MEM ATM CIP LVX AMK GEN TOB
43/97 >256 2 4 3 >256 0.75 3 8 0.032 2 0.064 4 1.5 0.125 0.125 4 4 4 96 16 TEM-52, TEM-1
1/98 >256 4 6 3 >256 0.5 4 8 0.032 2 0.064 4 3 0.064 0.094 >32 8 3 >256 6 TEM-52
405/01 >256 8 6 4 >256 0.5 3 8 0.032 4 0.250 3 0.5 0.094 0.38 >32 >32 4 >256 24 TEM-92
130/02 >256 2 6 2 >256 0.38 8 32 0.094 1 0.032 3 2 0.047 0.064 >32 16 3 >256 8 TEM-92, TEM-1
629/02 >256 8 12 4 >256 0.75 4 4 0.032 2 0.064 8 1 0.094 0.094 >32 >32 4 >256 24 TEM-92
139/03b >256 4 8 4 >256 0.5 4 8 0.032 2 0.064 32 1 0.064 0.125 >32 >32 4 >256 24 TEM-92
309/03b >256 4 8 4 >256 0.5 4 8 0.032 2 0.064 32 1 0.064 0.125 >32 >32 4 >256 24 TEM-92
463/03b >256 4 8 4 >256 0.5 4 8 0.032 2 0.064 32 1 0.064 0.125 >32 >32 4 >256 24 TEM-92
601/03 >256 2 4 4 >256 1 2 8 0.032 2 0.064 3 2 0.094 0.19 >32 >32 1.5 64 4 TEM-92, TEM-1
A19/03 >256 8 2 1.5 >256 0.75 2 4 0.032 2 0.064 2 2 0.047 0.047 0.75 2 3 96 8 TEM-92
A68/03 >256 4 4 6 >256 1 1.5 6 0.094 4 0.125 4 0.25 0.032 0.125 16 >32 1 64 4 TEM-92
65/99 >256 4 0.5 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 0.064 0.5 0.023 <0.016 0.016 0.032 1.5 0.5 0.75 TEM-1
1289/01 >256 4 3 1.5 0.5 0.19 <0.016 <0.016 <0.016 <0.016 <0.016 0.047 0.75 0.032 <0.016 1 4 1.5 12 2 TEM-1
2501/01 0.5 0.5 0.38 2 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 <0.016 1 0.032 <0.016 0.016 0.032 1 0.5 0.75 None
2512/01 0.5 0.5 0.38 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 <0.016 0.5 0.032 <0.016 0.016 0.032 1 0.5 0.75 None
108/02 >256 8 1.5 1.5 0.5 0.19 <0.016 <0.016 <0.016 <0.016 <0.016 0.032 1 0.023 <0.016 0.016 0.032 2 1 0.5 TEM-1
461/02 0.5 0.5 0.38 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 <0.016 0.75 0.032 <0.016 0.032 0.047 1.5 0.5 0.5 None
683/02 0.75 0.5 0.38 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 0.094 1 0.032 <0.016 0.016 0.032 2 0.5 0.75 None
794/02 >256 2 0.5 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 0.064 0.5 0.023 <0.016 0.016 0.032 6 128 32 TEM-1
85/03 1 1 0.38 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 0.032 1 0.032 <0.016 0.016 0.032 1.5 4 8 None
654/03 >256 2 0.5 2 0.38 0.19 <0.016 <0.016 <0.016 <0.016 <0.016 0.032 0.75 0.032 <0.016 0.016 0.032 0.5 1 0.5 TEM-1
753/03 0.5 0.5 0.38 1 0.125 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 <0.016 1 0.032 <0.016 0.016 0.032 2 0.5 0.75 None
A48/03 1 0.75 0.38 1 0.75 0.75 <0.016 <0.016 <0.016 <0.016 <0.016 <0.016 0.5 0.016 <0.016 0.016 0.032 1.5 2 1 None
134/04 >256 4 0.38 1 0.125 0.094 <0.016 <0.016 <0.016 <0.016 <0.016 0.047 1 0.032 <0.016 0.032 0.064 2 128 4 TEM-1
634/04 1 1 0.38 1 0.25 0.125 <0.016 <0.016 <0.016 <0.016 <0.016 0.023 1 0.032 <0.016 2 4 0.5 2 0.75 None
a

Abbreviations for antimicrobial agents follow (NCCLS 2004 breakpoints for susceptibility [S] and resistance [R] [in micrograms per milliliter] are given in parentheses): AMP, ampicillin (S ≤ 8, R ≥ 32); SAM, ampicillin plus sulbactam (S ≤ 8/4, R ≥ 32/16); AMC, amoxicillin plus clavulanate (S ≤ 8/4, R ≥ 32/16); FOX, cefoxitin (S ≤ 8, R ≥ 32); PIP, piperacillin (S ≤ 16, R ≥ 128); TZP, piperacillin plus tazobactam (S ≤ 16/4, R ≥ 128/4); CRO, ceftriaxone (S ≤ 8, R ≥ 64); CTX, cefotaxime (S ≤ 8, R ≥ 64); CTL, cefotaxime plus clavulanate; CAZ, ceftazidime (S ≤ 8, R ≥ 32); TZL, ceftazidime plus clavulanate; FEP, cefepime (S ≤ 8, R ≥ 32); IPM, imipenem (S ≤ 4, R ≥ 16); MEM, meropenem (S ≤ 4, R ≥ 16); ATM, aztreonam (S ≤ 8, R ≥ 32); CIP, eiprofloxacin (S ≤ 1, R ≥ 4); LVX, levofloxacin (S ≤ 2, R ≥ 8); AMK, amikacin (S ≤ 16, R ≥ 32); GEN, gentamicin (S ≤ 4, R ≥ 8); TOB, tobramycin (S ≤ 4, R ≥ 8).

b

These strains caused three different BSI in the same patient.